Xilio Therapeutics Future Growth
Future criteria checks 2/6
Xilio Therapeutics's earnings are forecast to decline at 22.3% per annum while its annual revenue is expected to grow at 22% per year. EPS is expected to grow by 10.5% per annum. Return on equity is forecast to be -30.1% in 3 years.
Key information
-22.3%
Earnings growth rate
10.5%
EPS growth rate
Biotechs earnings growth | 24.1% |
Revenue growth rate | 22.0% |
Future return on equity | -30.1% |
Analyst coverage | Low |
Last updated | 14 May 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3 | -121 | N/A | -91 | 4 |
12/31/2025 | 19 | -70 | N/A | -40 | 4 |
12/31/2024 | 30 | -35 | N/A | -36 | 1 |
3/31/2024 | N/A | -71 | -54 | -54 | N/A |
12/31/2023 | N/A | -76 | -69 | -69 | N/A |
9/30/2023 | N/A | -81 | -74 | -73 | N/A |
6/30/2023 | N/A | -84 | -81 | -80 | N/A |
3/31/2023 | N/A | -90 | -82 | -80 | N/A |
12/31/2022 | N/A | -88 | -78 | -76 | N/A |
9/30/2022 | N/A | -85 | -76 | -75 | N/A |
6/30/2022 | N/A | -82 | -77 | -75 | N/A |
3/31/2022 | N/A | -80 | -80 | -79 | N/A |
12/31/2021 | N/A | -76 | -82 | -81 | N/A |
9/30/2021 | N/A | -77 | -77 | -76 | N/A |
6/30/2021 | N/A | -75 | -67 | -66 | N/A |
3/31/2021 | N/A | -64 | -55 | -54 | N/A |
12/31/2020 | N/A | -55 | -38 | -36 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XLO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: XLO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: XLO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: XLO's revenue (22% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: XLO's revenue (22% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: XLO is forecast to be unprofitable in 3 years.